Overview of Ostofen

Property	Description
Active Ingredients	Ibuprofen, Ketoprofen
Form	Oral formulation (Tablet or Capsule)
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Use	Symptomatic relief from pain, inflammation, and fever
Origin	Synthetic compound

What Type of Medicine is Ostofen?

Ostofen is defined as a proprietary pharmaceutical preparation that belongs to the high-level Nonsteroidal Anti-inflammatory Drug (NSAID) pharmacological class. It is specifically characterized as a fixed-dose combination product, meaning it integrates two distinct, established active ingredients into a single unit. The chemical basis of both components places the medicine within the category of propionic acid derivatives.

Unlike standard single-agent NSAIDs, Ostofen employs a dual-component composition to engage the underlying physiological pathways responsible for discomfort. This strategy is clinically recognized for providing a comprehensive approach, leveraging the combined effects of two NSAID agents to manage symptoms. The identity as a combination preparation places it within a specific therapeutic approach focused on maximizing the effects of the NSAID class, often utilized when patients require relief from moderate, persistent discomfort.

Active Components and Origin

The core of Ostofen is built upon the active ingredients, Ibuprofen and Ketoprofen. Both agents are entirely synthetic compounds developed for their shared efficacy as an analgesic and anti-inflammatory agent. These APIs are integrated into an oral formulation, typically presented as a tablet or capsule. The simultaneous delivery of both Ibuprofen and Ketoprofen via the oral route of administration confirms its classification as a fixed-dose combination, streamlining the delivery approach for the patient.

General Purpose and Foundational Action

The general purpose of Ostofen is to provide symptomatic relief through its established actions as an analgesic (pain reducer), an anti-inflammatory agent, and an antipyretic (fever reducer). The foundational action of both active ingredients is to inhibit the body's production of prostaglandins, which are crucial chemical mediators of pain and inflammation. By effectively suppressing the biosynthesis of these signals, the medicine's dual action is intended to alleviate general discomfort and reduce the intensity of inflammatory responses, making it suitable for situations such as temporary relief from common musculoskeletal discomfort or general febrile states.

Regulatory References

NIH LiverTox NSAID Review

What side effects are possible with Ostofen?

Ostofen, a combination of Ibuprofen and Ketoprofen, shares the officially documented safety profile and constraints of the Nonsteroidal Anti-inflammatory Drug (NSAID) class, as defined by regulatory authorities like the FDA and EMA.

Adverse Reactions and Risk Classification

The most significant risks are detailed in Serious Adverse Reactions warnings, including the potential for Cardiovascular Thrombotic Events (such as myocardial infarction and stroke) and severe Gastrointestinal (GI) Events (such as ulceration, bleeding, and perforation). These risks are not static; the potential for serious CV events is documented to increase with the duration of use and is consistently observed at higher doses.

Common adverse reactions generally involve the Gastrointestinal System, including dyspepsia, nausea, abdominal pain, and flatulence. Other system-organ classes involved include Vascular (hypertension, fluid retention) and Nervous (headache, dizziness) systems. Rare, but documented, severe reactions include hepatic failure and serious skin conditions like Stevens-Johnson syndrome.

Safety Constraints and Risk Minimization

Official labeling enforces strict constraints to minimize risk. Regulatory documents mandate using the lowest effective dose for the shortest duration possible. Use is contraindicated for patients experiencing pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and for women in the third trimester of pregnancy. Furthermore, safety guidelines note that the medicine's activity may mask the diagnostic signs of an infection, potentially delaying appropriate intervention.

Overdose and Emergency Response

Overdose and When to Seek Help

The official prescribing information for Ostofen, a combination of Ibuprofen and Ketoprofen, documents specific manifestations of acute overdose. Documented clinical signs typically involve the Gastrointestinal (GI) system and the Central Nervous System (CNS). Reported symptoms include nausea, vomiting, abdominal pain, diarrhea, headache, drowsiness, confusion, and tinnitus.

Overdose can lead to severe or life-threatening outcomes. These documented complications include acute renal failure, metabolic acidosis, profound hypotension, and severe GI complications such as bleeding or perforation. The potential for seizures and coma is documented in cases of large overdose. Furthermore, official labeling notes that older adults are at an increased risk of severe gastrointestinal and renal outcomes.

The regulatory guidance mandates that anyone with a suspected overdose seek immediate medical attention. Urgent medical help must be sought for any severe signs, including difficulty breathing, slurred speech, signs of significant gastrointestinal bleeding (e.g., bloody vomit or black, tarry stools), or the onset of CNS symptoms like seizures or profound lethargy. Treatment is strictly symptomatic and supportive, as no specific antidote is known. Continuous monitoring of vital signs, neurological status, and laboratory parameters in a hospital setting is required.

Therapeutic Uses of Ostofen

What Ostofen Treats: Main Uses and Benefits

Symptomatic management is generally considered appropriate for conditions presenting with systemic or localized discomfort, such as pain and fever. This dual-NSAID formulation is commonly used to help manage symptoms related to inflammatory or irritative states. The medication is commonly used to help with musculoskeletal pain, rheumatoid arthritis, osteoarthritis, sprains, headaches, dental pain, and menstrual cramps (dysmenorrhea). It is applied in clinical settings where supportive symptom management is appropriate for conditions characterized by periods of heightened symptoms.

This approach is relevant for easing symptoms that interfere with daily functioning and helps address symptom clusters that may become intense or disruptive. It contributes to improved comfort during periods of heightened symptoms by easing the overall symptom load.

Symptom Focus:

Joint Stiffness

Managing Symptoms Across Key Domains

Ostofen may be applied across therapeutic domains involving localized discomfort and tissue inflammation, supporting patients during difficult episodes. It is relevant for easing systemic discomfort, specifically fever and generalized muscle aches associated with acute episodes. The medication helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ostofen?

Ostofen, a combination of Ibuprofen and Ketoprofen, is subject to eligibility rules mandated by regulatory bodies like the FDA and EMA. These rules define absolute contraindications and restrictions based on specific health conditions and demographics.

Contraindicated Populations (Must Not Use)

Contraindication Basis	Specific Population Restriction
Hypersensitivity	Patients with known allergy to Ibuprofen, Ketoprofen, or who experienced asthma or urticaria after taking aspirin or other NSAIDs.
GI Risk	Individuals with active or history of recurrent peptic ulcer or gastrointestinal hemorrhage/perforation.
Organ Failure	Patients with severe heart failure (NYHA Class IV), severe hepatic impairment, or severe renal failure.
Cardiovascular	Patients receiving pain treatment during the peri-operative period of Coronary Artery Bypass Graft (CABG) surgery.

Restricted and Conditional Use

Use of Ostofen is generally not recommended in the third trimester of pregnancy and during lactation/breastfeeding. Use in the pediatric population below the minimum labeled age is often not established or not recommended. Older adults (Geriatric) and patients with mild to moderate renal or hepatic impairment are subject to restricted use and require caution, as documented in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory authorities define Ostofen's interaction profile based primarily on the risk of Pharmacodynamic Reinforcement and Exposure Modification of co-administered agents. Due to the dual NSAID composition (Ibuprofen and Ketoprofen), co-administration with other NSAIDs, including COX-2 selective inhibitors, is explicitly discouraged or recommended to be avoided due to an increased risk of gastrointestinal bleeding.

Documented Interaction Patterns

Interacting Agent Category	Officially Documented Interaction Outcome
Anticoagulants, Corticosteroids, SSRIs	Increase the documented risk of gastrointestinal ulceration and bleeding.
Antihypertensives (ACE Inhibitors, ARBs, Diuretics)	May reduce the therapeutic effect; Diuretics also increase the risk of nephrotoxicity.
Lithium, Digoxin	Plasma concentrations of these agents may be increased due to reduced renal clearance.
Alcohol	Officially documented to increase the risk of serious GI bleeding.

Administration Constraints

The Ibuprofen component may competitively inhibit the anti-platelet effect of low-dose Aspirin, suggesting a need for non-concomitant dosing if appropriate. Furthermore, regulatory notes indicate that patients with impaired renal function, heart failure, or the elderly are at greatest risk of severe interactions, especially those involving nephrotoxicity when combined with agents like Diuretics.

Mechanism of Action

The mechanism of action for Ostofen is defined by the reversible, competitive inhibition of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes by its two active components. This inhibition blocks the initial enzymatic step in the Arachidonic Acid Cascade, thereby preventing the biosynthesis of Prostaglandins ( PGE2) and other eicosanoids. This molecular blockade is the essential step that alters subsequent physiological responses to mediators associated with nociception and thermoregulation.

Peripherally, the resulting drop in PGE2 reduces the PGE2-mediated sensitization of nociceptors, thereby reducing the excitability of these peripheral neurons. Centrally, the suppression of PGE2 synthesis in the hypothalamus resets the body's temperature control center. The Ketoprofen component also introduces a potential non-COX interaction that modulates central pain signaling, supporting an alteration of both peripheral and central components of nociceptive signaling.

Dosage and Administration Information

How to Use Ostofen

The administration of Ostofen (a fixed-dose combination of Ibuprofen and Ketoprofen) is strictly governed by official instructions, emphasizing the principle of using the lowest effective dose for the shortest duration necessary to manage symptoms. This approach aligns with official guidance for Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Official Administration Guidelines

Feature	Instruction from Official Documentation
Route of Administration	Oral route only (Tablet or Capsule formulation).
Dosing Schedule	Use the Lowest Effective Dose (LED) as needed. Do not exceed the Maximum Daily Dose specified on the product label.
Frequency and Interval	Doses must be separated by a minimum time interval, typically 4 to 8 hours, to maintain safe dosing limits.
Intake Condition	May be taken with food or milk to help reduce potential gastrointestinal irritation, as per standard NSAID labels.
Preparation	No dilution or preparation is required. The tablet or capsule must be swallowed whole.

Usage Constraints and Duration

Ostofen is intended for short-term use only, generally limited to no more than 10 days for acute pain or 3 days for fever without specialized professional monitoring. Official documentation advises specific modifications for vulnerable patient groups.

Older Adults (Geriatric): The lowest effective dose for the shortest possible duration is explicitly mandated for this population, owing to increased sensitivity to NSAID effects.
Organ Impairment: Dose reduction or avoidance is required in patients with pre-existing Renal or Hepatic impairment.

Failure to adhere to these maximum doses and time constraints constitutes use outside of the approved protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ostofen

The research base for Ostofen, a combination of Ibuprofen and Ketoprofen, focuses on evaluating its performance within the established class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). The available information is derived from studies that examined how symptoms change over time in conditions characterized by periods of heightened symptoms, as reported in official regulatory documents and peer-reviewed scientific literature.

Evidence for Use in Musculoskeletal Pain and Stiffness

Research exploring conditions involving physical discomfort and functional imbalance, such as muscle pain or joint stiffness, uses short-term randomized controlled trials (RCTs) and systematic reviews. These studies primarily focused on monitoring patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. Findings describe patterns observed in the studies related to measured changes in pain intensity over the short term. Research describes changes measured during the study period concerning patient movement and self-assessed functional status. However, research exploring short-term symptom changes typically had follow-up durations that were limited, generally not extending beyond 12 weeks.

Evidence for Acute Pain Conditions (Headache and Dental Pain)

Ostofen was studied for acute, temporary painful episodes, such as dental discomfort or headaches, using time-limited RCTs. These studies explored short-term symptom changes by measuring how quickly symptoms evolved in the observed populations. Outcomes examined were outcomes describing episodic or acute changes, including the total change in self-reported pain intensity and the time required for a noticeable change in discomfort. Trials reported measurements quantifying the magnitude and speed of short-term pain intensity changes in the acute setting.

Evidence for Symptomatic Relief in Menstrual Cramps (Dysmenorrhea)

The evidence for use in trials assessing short-term or episodic symptom patterns includes RCTs and systematic reviews focusing on outcomes capturing phases of heightened symptom activity in adult women with primary dysmenorrhea. Studies examined how symptoms changed over time, including pain intensity and associated systemic symptoms, such as nausea. Studies report how symptoms evolved in the observed populations during the acute symptomatic period. Subgroup findings are uncertain, as there is a lack of data for certain groups, such as adolescents or women with secondary dysmenorrhea.

Research Gaps and Unanswered Questions

The evidence landscape contains limitations for the fixed-dose combination product. There is limited information for long-term outcomes, and follow-up durations were limited across most trials. Comparative evidence is lacking when assessing the combination against a wide range of non-NSAID pain treatments. Furthermore, the evidence quality varies across studies, and data for certain groups remain insufficient, leaving unanswered questions regarding the product's use in patients with varying levels of comorbidity or specific age criteria. Research is ongoing to further contribute to the broader evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Ostofen (FAQ)

Q: How quickly does Ostofen start working after the first dose?

A: Official information regarding the active ingredients indicates that for certain formulations, a measurable onset of action has been described in certain study populations as occurring as early as 30 minutes. Generally, peak blood concentrations of the active components, which relate to maximum symptom relief, may be reached within 0.5 to 2 hours after the dose is taken.

Q: What is the typical time frame to see the expected benefits of Ostofen?

A: Ostofen is officially indicated for short-term symptomatic relief from pain and inflammation. Research studies typically assess the benefits over the short term, and regulatory guidance generally limits the use of this medicine for acute pain relief to 10 days or less. If symptoms persist beyond the short-term duration, regulatory documents suggest consulting with a healthcare professional.

Q: Do I need to take Ostofen at the same time every day?

A: Official dosing instructions emphasize the primary requirement for safe use: doses must be separated by a minimum time interval, typically 4 to 8 hours. It is mandated by official instructions that the maximum daily dose should not be exceeded. The focus is on maintaining a safe separation between doses rather than a fixed, rigid daily schedule.

Q: Can Ostofen be taken alongside common over-the-counter pain relievers?

A: Regulatory documents explicitly warn against taking Ostofen with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including other over-the-counter NSAID pain relievers. This is due to the documented increase in the risk of gastrointestinal bleeding. Official product information notes that combining multiple NSAID products is generally discouraged.

Q: Are there any specific foods or drinks that should be avoided while using Ostofen?

-A: Official documentation explicitly states that consuming alcohol is documented to increase the risk of serious gastrointestinal bleeding while taking Ostofen. This is the primary specific avoidance mentioned in relation to intake.

Q: Is it safe to consume alcohol while taking Ostofen?

A: Official product information contains a specific warning stating that alcohol consumption is documented to increase the risk of serious gastrointestinal bleeding. Official documentation includes an explicit warning regarding the combination of the medicine with alcohol intake.

Q: Are there any serious or less common side effects that I should be aware of with Ostofen?

A: Yes, official labeling details serious risks, which include the potential for Cardiovascular Thrombotic Events (such as heart attack and stroke) and severe Gastrointestinal Events (ulceration and bleeding). Rare, documented severe reactions also include conditions like hepatic failure or serious skin conditions.

Q: Can Ostofen affect my ability to drive or operate machinery?

A: Regulatory documents list central nervous system effects such as dizziness, somnolence (drowsiness), and headache as possible side effects. If a person experiences these reactions, it may impair their ability to drive or safely operate machinery.

Q: Does Ostofen affect blood pressure or heart rate?

A: Official adverse reaction profiles indicate that components of Ostofen can be associated with the onset or worsening of hypertension (high blood pressure) and fluid retention. While high blood pressure is a documented effect, official information does not consistently list specific effects on heart rate as a common reaction.

Q: Why is Ostofen prescribed for multiple conditions?

A: Ostofen is a fixed-dose combination that utilizes the proven analgesic (pain reducing), anti-inflammatory, and antipyretic (fever reducing) actions of its active ingredients. Because the medicine targets the common physiological pathways of pain and inflammation, it is suitable for providing symptomatic relief across various conditions that share these underlying features.

Q: Do younger adults or children have different eligibility requirements for Ostofen use?

-A: Yes, regulatory documents define specific restrictions for different age groups. Use in the pediatric population below the minimum labeled age is often not established or not recommended. Additionally, older adults (geriatric) are subject to restricted use, with a mandate to use the lowest effective dose for the shortest duration possible.

Q: Are there any tests or monitoring required while taking Ostofen?

A: Regulatory guidelines may recommend periodic monitoring of blood pressure in patients with pre-existing hypertension. Additionally, monitoring renal function (kidneys) may be recommended for high-risk patients, such as those with heart failure or those taking certain interacting co-medications.

Q: Is Ostofen known to cause weight gain or weight loss?

A: Weight change is not typically listed as a common side effect in official documents. However, fluid retention and edema (swelling due to fluid buildup) are documented adverse reactions associated with the medicine, which may lead to unusual weight gain.

Q: Is it possible to develop a dependency on Ostofen?

A: Ostofen is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), not a controlled substance, according to regulatory bodies. Its primary mechanism of action does not engage the neurological pathways typically associated with dependency found in opioid or other narcotic pain relievers.

Q: Can Ostofen cause changes in mood or sleep patterns?

A: Official adverse reaction tables list central nervous system effects such as insomnia and somnolence (drowsiness), which are changes in sleep patterns. Other documented effects include nervousness and confusion, which may indicate changes in mood or cognitive state.

Q: Is it known to interact with commonly used acid-reflux medications?

A: Regulatory documents note that the co-administration of antacids may slow the rate at which one of the active components (Ketoprofen) is absorbed into the body. This interaction does not typically alter the overall amount of medicine available to the system for immediate-release formulations.

Q: Does Ostofen cause dry mouth or changes in vision?

A: Official adverse reaction tables list 'Special Senses' effects, which can include changes in vision, as a reported side effect. However, dry mouth is not consistently listed as a common or frequently reported adverse reaction in regulatory documentation.

How should Ostofen be stored and disposed of?

Storage Requirements

Ostofen must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), as defined by regulatory standards. The medicine requires protection from environmental factors: it must be stored away from excess heat and moisture and should not be frozen. To maintain product integrity, keep Ostofen in its original container and ensure the container is tightly closed.

All medication must be stored out of the reach of children.

Disposal Instructions

To dispose of unused or expired Ostofen, utilize a drug take-back program. If a program is unavailable, authorities recommend mixing the medicine with an unappealing substance, such as dirt or used coffee grounds, placing the mixture in a sealed bag, and discarding it in the household trash. The medication should not be flushed down the toilet unless explicitly authorized by a regulatory body.

Ostofen